Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) Receives Average Recommendation of “Buy” from Brokerages
Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) has earned a consensus rating of “Buy” from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $37.00.
A number of analysts have weighed in on RHHBY shares. Zacks Investment Research raised shares of Roche Holdings AG Basel from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a report on Tuesday, July 9th. UBS Group raised shares of Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a report on Friday, July 26th. Deutsche Bank raised shares of Roche Holdings AG Basel from a “hold” rating to a “buy” rating in a report on Thursday, June 20th. Finally, Liberum Capital cut shares of Roche Holdings AG Basel from a “buy” rating to a “hold” rating in a report on Thursday, June 20th.
RHHBY stock traded down $0.66 during midday trading on Friday, reaching $34.57. 2,314,122 shares of the company were exchanged, compared to its average volume of 1,157,193. The company has a current ratio of 1.40, a quick ratio of 1.11 and a debt-to-equity ratio of 0.53. Roche Holdings AG Basel has a 1-year low of $25.10 and a 1-year high of $35.90. The company’s 50-day moving average price is $34.34. The company has a market capitalization of $236.85 billion, a P/E ratio of 14.90, a price-to-earnings-growth ratio of 2.26 and a beta of 0.48.
About Roche Holdings AG Basel
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Read More: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.